Crossref
Bimekizumab efficacy though 144 weeks in moderate to severe plaque psoriasis: results documented patients from the BE RADIANT study
Dermatologie pro praxi · 07.10.2024 · 18 (3) · 135-139
DOI: 10.36290/der.2024.027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatologie pro praxi, erschienen am 07.10.2024. Verfasst von Miloslav Salavec. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Salavec, M. (2024). Bimekizumab efficacy though 144 weeks in moderate to severe plaque psoriasis: results documented patients from the BE RADIANT study. Dermatologie pro praxi, 18(3), 135-139. https://doi.org/10.36290/der.2024.027
Vancouver
Salavec M. Bimekizumab efficacy though 144 weeks in moderate to severe plaque psoriasis: results documented patients from the BE RADIANT study. Dermatologie pro praxi. 2024;18(3):135-139. doi:10.36290/der.2024.027
BibTeX
@article{Salavec2024,
author = {Salavec, Miloslav},
title = {Bimekizumab efficacy though 144 weeks in moderate to severe plaque psoriasis: results documented patients from the BE RADIANT study},
journal = {Dermatologie pro praxi},
year = {2024},
volume = {18},
number = {3},
pages = {135--139},
doi = {10.36290/der.2024.027}
}
EUVIMED